Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ivologist vs NexLife

Ivologist
Graded #202

Lower grade

vs+2.6000000000000085
NexLife
Graded #139

Higher grade

The verdict

NexLife takes it — 68.7/100 to 66.1/100.

NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
71
71
Dose & formulationNexLife +12
52
64
Clinical oversightNexLife +5
84
89
Labs & monitoringEven
53
53
FulfillmentIvologist +18
85
67
Contract termsNexLife +18
37
55
Ivologist · left barNexLife · right bar

The numbers

MetricIvologistNexLife
WeighScore66.1/10068.7/100
GradeCC
Scorecard rank#202#139
Semaglutide$145/mo (compounded)$165/mo (compounded)
TirzepatideNot disclosed$215/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ivologist

Graded #202 · C

Strengths

  • LegitScript certified
  • All 50 states coverage
  • No monthly contracts, memberships, or autodrafts
  • Over 20,000 patients served
  • Both semaglutide and tirzepatide available

Where it loses points

  • No legal entity name or physical address disclosed on site
  • Broader platform — not a GLP-1 specialist
  • $25 deposit required to book the provider consultation (unclear whether it is credited toward the program)
NexLife

Graded #139 · C

Strengths

  • LegitScript certified platform
  • Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
  • Both semaglutide and tirzepatide at competitive pricing
  • Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset

Where it loses points

  • State availability not publicly disclosed
  • Compounded only — no brand-name options
  • Also covers hormone optimization and longevity
  • Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard